Home/Insights/Top Pharmaceutical Market Research Companies in the UAE

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in the UAE (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in the United Arab Emirates for 2026. This guide profiles 5 firms against the work pharmaceutical teams actually commission in the Emirates — MOHAP federal drug registration and price approval, formulary and tender positioning across the Department of Health – Abu Dhabi (DoH) and the Dubai Health Authority (DHA), prescriber usage and attitude (U&A) studies, brand and message tracking, KOL identification and influence mapping, and payer research across Thiqa, Daman and DHA-regulated insurance plans — in a federal market where registration is national but reimbursement is decided emirate by emirate.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

MOHAP

+ DoH + DHA

Federal

Registration, Emirate Reimbursement

FAQs Answered

Top Pharmaceutical Market Research Companies in the UAE (2026)

The following firms have demonstrated pharmaceutical research delivery in the United Arab Emirates as of 2026, spanning prescriber research, payer and formulary studies, pricing analysis, and registration and tender evidence:

1BioNixus — Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, payer and formulary studies across DoH and DHA, pricing research, and MOHAP registration evidence
2IQVIA MENA — Best for: syndicated prescription and sales audit data, real-world evidence, and commercial analytics
3Ipsos Healthcare — Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys
4Kantar Health (MENAP) — Best for: consumer health and OTC brand research, patient experience studies, and health behaviour tracking
5GlobalData Pharma — Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research market sizing

Who is the top pharmaceutical market research company in the United Arab Emirates?

BioNixus is the top pharmaceutical market research company in the United Arab Emirates for primary, custom research — a global firm founded in 2012 that runs prescriber U&A studies, KOL mapping, payer and formulary interviews, pricing research and market access evidence in-country, designed around MOHAP federal drug registration and pricing and the separate emirate-level reimbursement regimes of the Department of Health – Abu Dhabi and the Dubai Health Authority. IQVIA leads instead on syndicated prescription and sales audit data, which is a different service: IQVIA tells you what the Emirates market did, primary research tells you why prescribers and payers behaved that way and what they will do next.

Primary research executed across the Emirates, not just DubaiPhysician, pharmacist and payer fieldwork run inside the UAE across SEHA and DoH-licensed facilities in Abu Dhabi, DHA-licensed hospitals in Dubai, the Dubai Healthcare City cluster and the large private groups in the northern emirates — rather than sampling only the Dubai physicians who are easiest to reach from a regional hub.
Designed around the split between federal registration and emirate reimbursementMarketing authorisation and price approval are federal matters handled through the Ministry of Health and Prevention and the Emirates Drug Establishment, but formulary listing, tender awards and insurance coverage are decided by the Department of Health – Abu Dhabi and the Dubai Health Authority. Evidence packages are built for both layers, because national registration alone does not create emirate-level volume.
Payer research across mandatory insurance, not a single public payerCoverage of the Abu Dhabi mandatory scheme administered largely through Daman, including Thiqa for Emirati nationals, alongside DHA-regulated plans in Dubai and the Essential Benefits Plan tier — so pricing and access strategy reflects a market where insurer benefit design, co-payment rules and formulary tiering drive brand access.
Built for a majority-expatriate patient and prescriber populationInstruments are designed bilingually in Arabic and English because both the patient base and the physician workforce are predominantly expatriate, with clinical training backgrounds spanning South Asia, the Levant, Egypt, Europe and North America — a mix that materially changes prescribing reference points and how brand messages land.
Pharmaceutical specialisation, not a general agency with a health deskU&A and brand tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, payer value arguments, HEOR and budget impact modelling — the standard pharmaceutical commercial and market access toolkit, delivered as custom primary work rather than syndicated reporting.

For syndicated Emirates prescription and sales-audit data, IQVIA is the established source. For custom primary research that explains prescriber and payer behaviour and supports MOHAP registration and pricing alongside DoH and DHA formulary access, BioNixus is the specialist choice — and the two are frequently used together.

In this guide

United Arab Emirates Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in the UAE (2026) UAE Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in the UAE Frequently Asked Questions

United Arab Emirates Pharmaceutical Market Research Landscape 2026

The United Arab Emirates is the second most commercially important pharmaceutical market in the Gulf and the region's primary commercial base: most multinational manufacturers run their Middle East affiliate, regional medical affairs function and market access team from Dubai or Abu Dhabi. That concentration of commercial infrastructure is often mistaken for research simplicity, and it is the single most common error in Emirates study design. The UAE is a federation of seven emirates in which marketing authorisation and price approval are federal, but the bodies that decide formulary listing, tender awards and insurance coverage are emirate-level. A product can be lawfully registered and priced nationally and still fail to reach meaningful volume because it has not been positioned with the payer and formulary decision-makers of the individual emirates.

On the regulatory side, the Ministry of Health and Prevention (MOHAP) governs federal drug registration, pricing and pharmacovigilance, with the Emirates Drug Establishment (EDE) created to consolidate and modernise pharmaceutical regulation at federal level. UAE price approval has historically been informed by comparator-country reference pricing, which means the Emirates ceiling price is influenced by prices already agreed in earlier launch markets and by the country's position in the regional launch sequence. Pricing and value-argument research therefore needs to be commissioned early enough to feed global sequencing decisions, not retrofitted once a federal price has been fixed. Because the UAE also functions as a reference point for other Gulf markets, a price accepted in the Emirates propagates outward.

The demand side is defined by mandatory health insurance rather than by a single centralised government purchaser, and it differs by emirate. In Abu Dhabi, the Department of Health (DoH) regulates a mandatory insurance market in which Daman is the dominant administrator, operating the Thiqa programme for Emirati nationals alongside basic and enhanced plans for expatriate residents, while public provision runs largely through the SEHA network including Sheikh Khalifa Medical City, Tawam Hospital and Sheikh Shakhbout Medical City, plus Cleveland Clinic Abu Dhabi. In Dubai, the Dubai Health Authority regulates mandatory cover including the low-cost Essential Benefits Plan tier and manages the emirate's own drug approval and formulary process across DHA-licensed hospitals such as Dubai Hospital, Rashid Hospital and Latifa Hospital, while Dubai Healthcare City operates under its own regulatory authority. The northern emirates rely more heavily on MOHAP-run facilities and private groups. Each of these environments applies different benefit design, co-payment rules and formulary tiering to the same molecule.

The practical consequence for selecting a research partner is that the Emirates rewards genuine multi-emirate execution and punishes convenience sampling. Prescriber recruitment must span DoH and SEHA facilities in Abu Dhabi, DHA hospitals and the private Dubai cluster, and MOHAP facilities and private groups in Sharjah, Ajman and Ras Al Khaimah; payer interviews must reach insurer medical directors and formulary committee members in both Abu Dhabi and Dubai; and the near-total dominance of expatriate physicians and patients requires bilingual Arabic-English instruments and stratified sampling to avoid a distorted read. Many firms serve the UAE from a Dubai commercial office and supply data and analytics competently, yet consistently under-deliver on the multi-emirate primary fieldwork that launch, pricing and access decisions actually rest on.

5 Pharmaceutical Market Research Companies in the UAE (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: USA (HQ) / UK / Middle East

Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, payer and formulary studies across DoH and DHA, pricing research, and MOHAP registration evidence

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with offices in the UK and the Middle East. In the United Arab Emirates it delivers custom primary research: prescriber usage and attitude studies, brand and message tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, payer and formulary committee research across the Department of Health – Abu Dhabi and the Dubai Health Authority, pricing and willingness-to-pay research, and health economics and outcomes research supporting market access. Study designs treat the UAE as what it is — a federal registration market with emirate-level payers — so evidence is structured both for MOHAP and Emirates Drug Establishment registration and price approval and for the separate formulary, tender and insurance decisions taken in Abu Dhabi and Dubai. Fieldwork is executed in-country in Arabic and English across SEHA and DoH-licensed facilities, DHA hospitals, the Dubai Healthcare City cluster, and private hospital groups in the northern emirates, with sampling stratified to reflect a predominantly expatriate prescriber and patient population.

Key strengths

Prescriber U&A, brand tracking and therapy area landscaping executed across all seven emirates
Physician recruitment spanning SEHA and DoH facilities, DHA hospitals, DHCC and private groups
Payer and formulary research across Daman and Thiqa in Abu Dhabi and DHA-regulated plans in Dubai
Pricing and willingness-to-pay research aligned to MOHAP price approval and reference pricing
Emirate-level tender and procurement intelligence for DoH and DHA institutional volume
KOL identification, influence mapping and advisory board recruitment across Emirates specialty networks
HEOR, budget impact and cost-effectiveness evidence for insurer and formulary submissions
Arabic-English bilingual instrument design and moderation for an expatriate-majority prescriber base

IQVIA MENA

Healthcare Data & Analytics CompanyHQ: USA (global) / UAE regional hub (Dubai)

Best for: syndicated prescription and sales audit data, real-world evidence, and commercial analytics

IQVIA is the largest healthcare data and analytics company globally and runs its MENA regional operation from the UAE, which makes the Emirates one of its best-served markets for syndicated data. Its core value locally is longitudinal sales and prescription audit data, market sizing and brand share tracking across the retail pharmacy and hospital channels, real-world evidence programme design, and commercial analytics including territory design and sales force sizing. For a manufacturer that needs to know what the Emirates market did — volumes, shares, channel splits, private versus institutional trend lines — IQVIA is the established reference. Its custom qualitative and payer primary capability is comparatively thin relative to the data business, and because its UAE team also carries regional coverage, emirate-level formulary and insurer nuance tends to be treated as a market-intelligence overlay rather than as fieldwork. It is most often used alongside a primary research specialist rather than instead of one.

Key strengths

Syndicated pharmaceutical sales and prescription audit data for the UAE
Retail pharmacy and hospital channel analytics and brand share tracking
Real-world evidence design and secondary data analysis
Regulatory and market intelligence covering MOHAP and Gulf registration pathways
Commercial effectiveness, territory design and sales force analytics from a Dubai base

Ipsos Healthcare

Global Market Research Network — Healthcare DivisionHQ: France (global) / UAE regional hub

Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys

Ipsos Healthcare is the pharmaceutical-facing division of Ipsos and covers the United Arab Emirates from its regional hub. Its recognised strengths are syndicated therapy-area monitors and patient record or chart audit programmes that track treatment patterns at scale within defined disease areas, plus large quantitative prescriber surveys fielded on global panel infrastructure. Where the UAE is one market in a multi-country set and the requirement is standardised, comparable treatment-pattern data, Ipsos is a credible option. Depth on Emirates access mechanics is more limited: DoH and DHA formulary process, Daman and Thiqa benefit design, MOHAP price approval and emirate tendering sit outside its core offer, and panel-sourced samples in the UAE tend to over-represent accessible private-sector physicians in Dubai relative to Abu Dhabi institutional prescribers and the northern emirates.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking including UAE coverage
Patient chart and medical record audit programmes
Large-scale quantitative prescriber surveys via global panels
Multi-country study design with consistent cross-market comparability
Brand equity and message tracking for pharmaceutical brands

Kantar Health (MENAP)

Global Market Research Network — Health PracticeHQ: UK (global) / UAE regional hub

Best for: consumer health and OTC brand research, patient experience studies, and health behaviour tracking

Kantar's health practice operates across MENAP and serves the United Arab Emirates from its regional hub. Its centre of gravity is the consumer end of pharmaceutical marketing, and the Emirates is a strong fit for that: a large, affluent, retail-pharmacy-driven OTC market with high self-medication and supplement usage across a multinational resident base. Kantar delivers OTC and consumer health brand tracking, patient experience and treatment decision research, adherence and health behaviour studies, and advertising and claims testing, supported by substantial GCC panel infrastructure and multilingual consumer reach. For prescription-medicine access questions — insurer negotiation, DoH and DHA formulary positioning, MOHAP price approval, emirate tender strategy — it is markedly less specialised than firms built around pharmaceutical market access.

Key strengths

OTC and consumer health brand tracking across the UAE retail pharmacy channel
Patient experience, adherence and treatment decision research
Advertising, claims and communications testing for the Emirates market
Large-scale multilingual consumer health behaviour surveys
GCC-wide consumer panel and sample infrastructure

GlobalData Pharma

Syndicated Intelligence & Analytics ProviderHQ: UK (global)

Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research market sizing

GlobalData supplies syndicated pharmaceutical intelligence covering drug pipelines, clinical trial activity, competitor profiling, deals and therapy-area forecasts, with the United Arab Emirates included in its Middle East coverage. It is a useful and comparatively low-cost input for early opportunity assessment, competitive landscaping and business development screening, particularly for teams building a regional entry case from a UAE base. It does not conduct primary fieldwork: there are no prescriber interviews, no insurer or formulary research, and no emirate-level access studies, so its country coverage necessarily treats the UAE as a single market and cannot surface the Abu Dhabi versus Dubai divergence that determines actual reimbursement outcomes.

Key strengths

Drug pipeline and clinical trial intelligence
Competitor profiling and deal tracking
Therapy-area forecasts and desk-research market sizing
Middle East market coverage within global datasets

UAE Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA MENA	Ipsos Healthcare	Kantar Health	GlobalData
Custom primary prescriber research (U&A)	Core capability	Limited — data-led	Yes — panel-based	Consumer health focus	None
Multi-emirate fieldwork beyond Dubai	Yes — all seven emirates	Dubai hub	Dubai hub	Dubai hub	No
MOHAP registration & price approval evidence	Yes — submission-aligned	Regulatory intelligence	Partial	No	Desk research only
DoH Abu Dhabi & DHA formulary research	Yes — both regulators	Market intelligence	Limited	Limited	No
Insurer payer research (Daman / Thiqa / DHA plans)	Yes	Partial	Limited	No	No
Syndicated sales & prescription audit data	Not offered — primary specialist	Core capability	Chart audits	No	Forecasts only
Arabic-English bilingual qualitative moderation	Yes — native	Partial	Partial	Yes	No
HEOR & budget impact modelling	Yes	Yes — separate practice	Limited	No	No

What Decides Pharmaceutical Research Quality in the UAE

Federal Registration Does Not Buy Emirate-Level Access

Marketing authorisation and price approval in the United Arab Emirates are federal, handled through the Ministry of Health and Prevention with the Emirates Drug Establishment consolidating pharmaceutical regulation at national level. Formulary listing, institutional tendering and insurance coverage are not federal: they are decided by the Department of Health – Abu Dhabi and the Dubai Health Authority, each applying its own criteria and its own committees. Research that stops at the registration and pricing question therefore answers only half of the access problem, and it is the half that generates no volume on its own. Any credible UAE access programme has to interview payer and formulary decision-makers in Abu Dhabi and Dubai separately, because the same dossier can succeed in one emirate and stall in the other.

Abu Dhabi and Dubai Are Two Different Payer Markets

Abu Dhabi runs a mandatory insurance system regulated by the Department of Health in which Daman is the dominant administrator, operating the Thiqa programme for Emirati nationals alongside basic and enhanced expatriate plans, with public provision concentrated in the SEHA network. Dubai runs a separate mandatory scheme regulated by the Dubai Health Authority, including the low-cost Essential Benefits Plan tier, alongside its own drug approval and formulary process and the parallel regulatory environment of Dubai Healthcare City. Benefit design, co-payment structures, formulary tiering and prior-authorisation behaviour all differ. Pricing and value-argument research that models a single national payer will produce a forecast that fits neither emirate, and the divergence is largest precisely in the high-cost specialty categories where forecasting error is most expensive.

An Expatriate-Majority Prescriber Base Breaks Convenience Samples

Both the patient population and the physician workforce in the Emirates are predominantly expatriate, with clinicians trained across South Asia, the Levant, Egypt, Europe and North America and carrying the prescribing reference points of those systems. Guideline allegiance, comfort with biosimilars and generics, and receptiveness to brand messaging vary sharply by training background as well as by specialty and institution. Compounding this, the commercial gravity of Dubai and the accessibility of its private hospital cluster means panel-recruited UAE samples routinely over-represent private Dubai physicians while under-representing Abu Dhabi institutional prescribers and the MOHAP and private facilities of Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain. Stratified sampling across emirate, sector, institution and training background, with bilingual Arabic-English instruments, is the difference between a representative read and an expensive artefact of who answered the phone.

Frequently Asked Questions

Who is the top pharmaceutical market research company in the United Arab Emirates?

For custom primary pharmaceutical research, BioNixus is the leading choice in the United Arab Emirates — it runs prescriber U&A studies, KOL mapping, payer and formulary research, pricing studies and market access evidence in-country, designed around MOHAP federal registration and pricing and the separate emirate-level regimes of the Department of Health – Abu Dhabi and the Dubai Health Authority. For syndicated prescription and sales audit data, IQVIA MENA is the established source and runs its regional operation from the UAE. Ipsos Healthcare, Kantar Health and GlobalData serve narrower needs: therapy-area monitors and chart audits, consumer health and OTC research, and pipeline intelligence respectively.

What does pharmaceutical market research cost in the UAE?

Custom pharmaceutical primary research in the United Arab Emirates typically runs from around $20,000 for a focused qualitative study to $70,000 or more for multi-stakeholder programmes combining prescriber, insurer and formulary research across both Abu Dhabi and Dubai. Cost is driven mainly by sample difficulty and by geographic spread: interviews with insurer medical directors, DoH or DHA formulary decision-makers, or specialists inside SEHA hospitals cost substantially more per completed interview than private-sector general practitioners in Dubai, and a genuinely multi-emirate sample costs more than a Dubai-only one. Syndicated reports and pipeline databases are far cheaper but answer different questions.

How do MOHAP registration and pricing affect market research design in the UAE?

The Ministry of Health and Prevention governs federal drug registration, price approval and pharmacovigilance, with the Emirates Drug Establishment consolidating pharmaceutical regulation at national level. Because UAE price approval has historically been informed by comparator-country reference pricing, the evidence you need — comparator positioning, value arguments, willingness-to-pay across insurers and institutional purchasers — has to be generated before the federal price is submitted, and ideally before prices are set in the reference markets that inform it. The UAE also acts as a reference point for other Gulf markets, so an Emirates price propagates regionally. Research supporting a UAE submission should be scoped alongside the global and regional launch sequence rather than as a local afterthought.

Who are the payers for pharmaceuticals in the UAE?

The UAE has no single national pharmaceutical payer. In Abu Dhabi, the Department of Health regulates a mandatory insurance market in which Daman is the dominant administrator, operating Thiqa for Emirati nationals alongside basic and enhanced plans for expatriate residents, while public provision runs largely through the SEHA network. In Dubai, the Dubai Health Authority regulates mandatory cover including the Essential Benefits Plan tier and manages its own drug approval and formulary process across DHA-licensed hospitals. The northern emirates rely more on MOHAP facilities and private providers. Access strategy and pricing research must address each of these separately, because insurer benefit design, formulary tiering and prior-authorisation practice differ by emirate.

How do you recruit UAE physicians for pharmaceutical research?

Credible Emirates prescriber research has to reach beyond the accessible private hospitals of Dubai into SEHA and DoH-licensed facilities in Abu Dhabi, DHA hospitals such as Dubai Hospital and Rashid Hospital, the Dubai Healthcare City specialist cluster, and MOHAP and private facilities in the northern emirates. That depends on established in-country networks and appropriate institutional permissions, and on bilingual instruments: most UAE physicians are expatriates working in English while patient-facing context is frequently Arabic. Sampling should also be stratified by training background, because prescribing reference points differ markedly between clinicians trained in South Asia, the Levant, Europe and North America. BioNixus maintains UAE physician networks across these channels and moderates qualitative work in both languages.

What is the Emirates Drug Establishment and why does it matter for research?

The Emirates Drug Establishment (EDE) was created to consolidate and modernise pharmaceutical regulation at federal level in the United Arab Emirates, working alongside the Ministry of Health and Prevention on registration, pricing and pharmacovigilance. For research planning, its significance is that it strengthens the federal layer of the market without altering the emirate-level layer: registration and price approval become more centralised, while formulary listing, institutional tendering and insurance coverage remain matters for the Department of Health – Abu Dhabi and the Dubai Health Authority. Evidence programmes therefore still need two audiences — a federal registration and pricing dossier, and emirate-specific payer and formulary value arguments.

How is pharmaceutical research different from healthcare market research in the UAE?

Healthcare market research in the Emirates covers the broader system — hospital groups and providers, medical devices, patient experience, medical tourism and consumer health across a highly diverse population. Pharmaceutical market research is narrower and deeper: it centres on prescription medicines and the specific mechanics that govern them, meaning MOHAP registration and price approval, DoH and DHA formulary listing, insurer coverage and co-payment tiering under Daman, Thiqa and DHA-regulated plans, prescriber usage and attitudes, brand and message tracking, KOL influence mapping, and payer value arguments including HEOR and budget impact. Teams launching or defending a prescription product in the Emirates need the pharmaceutical-specific version.

Does BioNixus conduct pharmaceutical market research in the UAE?

Yes. BioNixus delivers custom pharmaceutical market research across the United Arab Emirates for pharmaceutical, biotech and medical device clients, including prescriber U&A and brand tracking, KOL identification and influence mapping, payer and formulary research across DoH Abu Dhabi and DHA Dubai and the insurers that operate under them, pricing and willingness-to-pay studies aligned to MOHAP price approval, emirate-level tender intelligence, and HEOR and budget impact evidence. Fieldwork is run in-country in Arabic and English with sampling stratified across emirates, sectors and prescriber training backgrounds. Contact us to discuss a UAE pharmaceutical research scope.

Related Resources

Top Market Research Companies in the UAE

Top Healthcare Market Research Companies in Dubai

Top Healthcare Market Research Companies in Abu Dhabi

Top Market Research Companies in Dubai

Top Market Research Companies in Abu Dhabi

Top Pharmaceutical Market Research Companies in Saudi Arabia

Top Pharmaceutical Market Research Companies in Qatar

GCC Market Access Guide

Request a UAE Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in the UAE

BioNixus runs custom pharmaceutical research across all seven emirates — prescriber U&A and brand tracking, KOL mapping, payer and formulary studies across DoH Abu Dhabi and DHA Dubai, pricing research aligned to MOHAP price approval, and emirate-level tender intelligence.

Request a Proposal